gdc
FDA Approvals, News & UpdatesOvarian Cancer

Zejula Now Approved as First-Line Maintenance Therapy in All Patients with Ovarian Cancer

In April 2020, the FDA approved Zejula for long-term maintenance therapy for all patients with advanced ovarian cancer, regardless of any gene mutations.
June 2020 Vol 6 No 3

On April 29, 2020, the FDA approved Zejula (niraparib; from GlaxoSmithKline), an oral PARP inhibitor, as the first PARP inhibitor approved for first-line maintenance (long-term) therapy for all patients with advanced ovarian cancer (including epithelial ovarian, fallopian tube, or primary peritoneal cancer) whose cancer had a complete or partial response to platinum-based chemotherapy. Zejula was previously approved for several types of ovarian cancer, including patients with HRD-positive disease, defined by the presence of the BRCA gene mutation or genomic instability.

Since late 2018, women with ovarian cancer and a BRCA mutation whose cancer responded to initial treatment with chemotherapy were eligible to receive treatment with a PARP inhibitor, including Zejula or Lynparza (olaparib).

This approval was based on the results of a clinical trial of 733 patients with ovarian cancer who had a response to first-line platinum-based chemotherapy. Patients received first-line maintenance treatment with Zejula or with placebo.

The results showed significantly longer time without cancer progression in patients who received Zejula compared with patients who received placebo, regardless of HRD status. The average time without cancer progression in patients with HRD-positive status was 21.9 months with Zejula versus 10.4 months with placebo. The average time without cancer progression in all the patients was 13.8 months with Zejula versus 8.2 months with placebo.

The most common side effects with Zejula in the PRIMA study were thrombocytopenia (reduced platelets), anemia, nausea, fatigue, neutropenia, constipation, muscle pain, headache, insomnia, vomiting, dyspnea, decreased appetite, dizziness, cough, hypertension, and kidney injury.

Share this:

Recommended For You
Breast CancerFDA Approvals, News & Updates
FDA Approved Margenza for Patients with Metastatic HER2-Positive Breast Cancer
In December 2020, the FDA approved Margenza (margetuximab-cmkb), a new targeted therapy, for the treatment of patients with metastatic HER2-positive breast cancer, representing an important new option for patients with this type of breast cancer that continues to progress despite different treatments.
FDA Approvals, News & UpdatesLung Cancer
FDA Approves Tepmetko, New Targeted Therapy, for Patients with Metastatic Lung Cancer and MET Exon 14 Alterations
In February 2021, the FDA approved Tepmetko (tepotinib), a new oral targeted therapy, for the treatment of all adults with metastatic non–small-cell lung cancer and MET exon 14 alterations. Tepmetko is the first MET inhibitor that has been approved by the FDA.
FDA Approvals, News & UpdatesLung Cancer
Tagrisso Approved as Adjuvant Therapy for Patients with Lung Cancer and EGFR Mutations
In December 2020, the FDA approved Tagrisso (osimertinib) for adjuvant therapy (continued therapy to prevent cancer recurrence) after surgical removal of the tumor, in patients with non–small-cell lung cancer and EGFR exon 19 deletions or exon 21 L858R mutations. Tagrisso was previously approved for the treatment of other types of lung cancer.
FDA Approvals, News & UpdatesProstate Cancer
Orgovyx First FDA-Approved Oral Hormone Therapy for Patients with Advanced Prostate Cancer
In December 2020, the FDA approved Orgovyx (relugolix), as the first oral hormone therapy for the treatment of men with advanced prostate cancer. This new drug may eliminate the need to visit the clinic for treatment, helping patients with cancer avoid unnecessary exposure during the pandemic.
Last modified: July 7, 2020

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country